Epigral, a company in the Specialty Chemicals industry, reported revenue of ₹746 crore and net profit of ₹64 crore for the September 2026 quarter.
Epigral (NSE: EPIGRAL) closed at ₹928.30 on 20 Nov 2026, down 36.2% over the past year. Its market capitalisation is ₹4,005 crore and it trades at 14.1 times earnings.
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.